Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.

Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.

Publication date: Feb 06, 2019

Randomised controlled trials (RCTs) of adjunctive vitamin D in pulmonary tuberculosis (PTB) treatment have yielded conflicting results. Individual participant data (IPD) meta-analysis could identify factors explaining this variation.

We meta-analysed IPD from RCTs of vitamin D in patients receiving antimicrobial therapy for PTB. Primary outcome was time to sputum culture conversion. Secondary outcomes were time to sputum smear conversion, mean 8-week weight and incidence of adverse events. Pre-specified sub-group analyses were done according to baseline vitamin D status, age, sex, drug-susceptibility, HIV status, extent of disease, and vitamin D receptor genotype.

IPD were obtained for 1850 participants in 8 studies. Vitamin D did not influence time to sputum culture conversion overall (aHR 1.06, 95% CI 0.91-1.23), but it did accelerate sputum culture conversion in participants with multidrug-resistant PTB (aHR 13.44, 95% CI 2.96-60.90); no such effect was seen in those whose isolate was sensitive to rifampicin and/or isoniazid (aHR 1.02, 95% CI 0.88-1.19; P=0.02). Vitamin D accelerated sputum smear conversion overall (aHR 1.15, 95% CI 1.01-1.31), but did not influence other secondary outcomes.

Vitamin D did not influence time to sputum culture conversion overall, but it accelerated sputum culture conversion in patients with multidrug-resistant PTB.

Jolliffe, D.A., Ganmaa, D., Wejse, C., Raqib, R., Haq, M.A., Salahuddin, N., Daley, P.K., Ralph, A.P., Ziegler, T.R., and Martineau, A.R. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data. 04738. 2019 Eur Respir J.



Please signin to view all article content and metadata.


Leave a Comment

Your email address will not be published. Required fields are marked *